{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:38:13Z","timestamp":1762101493125,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2181,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["570893"],"award-info":[{"award-number":["570893"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt474","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T09:52:28Z","timestamp":1385027548000},"page":"x64-x68","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S10","title":["Patient-reported outcomes in ovarian cancer clinical trials"],"prefix":"10.1016","volume":"24","author":[{"given":"M.L.","family":"Friedlander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2006","series-title":"Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"United States Food and Drug Administration","key":"10.1093\/annonc\/mdt474_bb0010"},{"key":"10.1093\/annonc\/mdt474_bb0015","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2012.45.9792","article-title":"Comparative effectiveness research in oncology: an overview","volume":"30","author":"Lyman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt474_bb0020","unstructured":"EMEA Committee for Medicinal Products for Human Use (CMHP) Doc Ref EMEA\/CHMP\/EWP\/139391\/2004LondonEuropean Medicines Agency; 2005. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products."},{"key":"10.1093\/annonc\/mdt474_bb0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1741-7015-9-86","article-title":"Measuring patient reported outcomes: moving beyond misplaced common sense to hard science","volume":"9","author":"McKenna","year":"2011","journal-title":"BMC Med"},{"key":"10.1093\/annonc\/mdt474_bb0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ygyno.2010.07.009","article-title":"Symptom research in gynecologic oncology: a review of available measurement tools","volume":"119","author":"Agarwal","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt474_bb0035","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1200\/JCO.2007.11.0197","article-title":"Use of patient reported outcomes in phase 3cancer treatment trials: lessons learned and future directions","volume":"25","author":"Ganz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdt474_bb0040","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1111\/j.1524-4733.2007.00269.x","article-title":"Patient-reported outcomes: conceptual issues","volume":"10","author":"Rothman","year":"2007","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdt474_bb0045","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1016\/j.ejca.2010.08.002","article-title":"Choosing patient-reported outcome measures for cancer clinical research\u2014practical principles and an algorithm to assist non-specialist researchers","volume":"46","author":"Luckett","year":"2010","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdt474_bb0050","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11136-010-9793-3","article-title":"Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers","volume":"20","author":"Brundage","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1093\/annonc\/mdt474_bb0055","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt474_bb0060","series-title":"Outcome Research in Cancer: Measures Methods and Applications","first-page":"14","article-title":"Definitions and conceptual models of quality of life","author":"Ferrans","year":"2005"},{"key":"10.1093\/annonc\/mdt474_bb0065","unstructured":"Effectiveness Guidance DocumentRecommendations for incorporating Patient Reported Outcomes(PRO's) into Clinical Comparative Effectiveness Research(CER) in Adult Oncology Published Version 1.0 May 2012www.cmptnet.org"},{"issue":"10","key":"10.1093\/annonc\/mdt474_bb0070","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","article-title":"Heading G Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations","volume":"22","author":"Luckett","year":"2011","journal-title":"Ann Oncol (IF 5.647)"},{"key":"10.1093\/annonc\/mdt474_bb0075","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt474_bb0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1081\/CNV-120022366","article-title":"What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN)","volume":"21","author":"Cella","year":"2003","journal-title":"Cancer Invest"},{"issue":"18S","key":"10.1093\/annonc\/mdt474_bb0085","first-page":"16021","article-title":"Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer","volume":"25","author":"Beaumont","year":"2007","journal-title":"J Clin Oncol ASCO Annual Meeting Proceedings Part I"},{"issue":"2","key":"10.1093\/annonc\/mdt474_bb0090","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","volume":"120","author":"Jensen","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdt474_bb0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdt474_bb0100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt474_bb0105","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/S0959-8049(03)00307-1","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer","volume":"39","author":"Greimel","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt474_bb0110","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2013results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt474_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdt474_bb0120","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"Gynecologic cancer intergroup 2010 gynecologic cancer interGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"34","key":"10.1093\/annonc\/mdt474_bb0125","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt474_bb0130","article-title":"Practical and statistical issues in missing data for longitudinal patientreported outcomes","author":"Bell","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1093\/annonc\/mdt474_bb0135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared With gemcitabine on quality of life in patients With metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdt474_bb0140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/etm.2011.368","article-title":"Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: a meta-analysis of randomized controlled trials","volume":"3","author":"Matsuda","year":"2012","journal-title":"Exp Ther Med"},{"issue":"9804","key":"10.1093\/annonc\/mdt474_bb0145","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(11)61256-7","article-title":"Reporting quality of life in clinical trials: a CONSORT extension","volume":"378","author":"Calvert","year":"2011","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341937396X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341937396X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/suppl_10\/x64\/6675290\/mdt474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:06:17Z","timestamp":1582178777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341937396X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":28,"alternative-id":["S092375341937396X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt474","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}